Joincare Pharmaceutical (SHA:600380) said China's drug regulator accepted the market authorization application for laichangqita monoclonal antibody injection, according to a Tuesday filing with the Shanghai bourse.
The drug, jointly developed by subsidiary Livzon Monoclonal and Beijing Xinkanghe, is used for treating ankylosing spondylitis.
This marked the drug's second accepted indication after psoriasis.
Shares of the pharmaceutical company were down 1% in recent trade.
South Korea's alcohol expenditures fell at its sharpest pace in seven years during the first quarter of the year, according to data reported by Statistics Korea, as cited by the Yonhap News Agency on Tuesday.The decline in consumption was attributed to a change in drinking habits, the report added.Households' alcohol consumption came in at 13,000 won per month on average, representing a 9% year over year decline, the report said.Meanwhile, shipments of alcoholic beverages in the country dropped by over 17% from a decade earlier to 3.15 million kiloliters in 2024, the report noted.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
SRG Global's (ASX:SRG) guidance upgrade continues to demonstrate the strength of the company's diversified infrastructure services model, according to a Tuesday Euroz Hartleys note.The company on Tuesday upgraded its fiscal year 2026 guidance after securing AU$1.85 billion of contracts with blue-chip clients in a range of sectors.The upgrade beats Euroz Hartleys' current underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) forecast, and the research firm said it is looking at its forecasts with an upward bias.Euroz Hartleys kept a buy rating on SRG Global and an under review price target of AU$3.51.The company's shares rose 16% to a new all-time high in recent Tuesday trade.
Energy World (ASX:EWC) agreed to sell its Siemens gas and steam turbines for $350 million to NASDAQ-listed Hallador Energy, according to a Tuesday Australian bourse filing.Under the terms of the sale, the gas turbines are required to be inspected and refurbished by a recognised original equipment maintenance provider in the US. Hallador agreed to fund the baseline estimate of $22 million, and additional work costs of up to a further $22 million will be shared equally between both firms.Dismantling and export costs will be for Energy World's account, but funded by Hallador from the consideration. Transportation and importation costs will be shouldered by Hallador in addition to the purchase price.The sale represents the execution of a strategic review and evaluation of monetization opportunities across its asset base, per the filing.